The Number Statins Can't Touch: What Oral Estradiol Taught Me About Lipoprotein(a)
There's a moment I love in this work, the moment a patient's labs come back and the number that's been haunting them for years has actually moved.
That happened recently with a patient of mine. She came to me with a lipoprotein(a) also called Lp(a) in the 90s, this is too high and increases her risk of heart disease and stroke. If you know Lp(a), you know that number is not small talk. It's a genetically determined, largely fixed cardiovascular risk marker that diet, exercise, and most of our best lipid lowering drugs simply cannot touch. We optimized her with oral estradiol as part of her bioidentical hormone therapy plan, no statin added and nothing else changed on the lipid side. Four months later, her Lp(a) was 33. Not just improved but nearly an undetectable range for practical risk purposes.
I've seen this pattern enough times now that I don't think of it as a fluke. And when I went back to the cardiovascular literature to understand why it happens and why it happens with oral estrogen specifically, not the patch or the cream, the mechanism turned out to be well documented. It just hasn't made its way into the mainstream conversation about menopause care.
Why Lp(a) Is the Risk Factor Nobody Can Treat, Yet
Lp(a) is one of the strongest independent, genetically driven risk factors we have for atherosclerosis and cardiovascular disease. Unlike LDL, it doesn't respond meaningfully to statins, ezetimibe, lifestyle change, or diet. For decades, cardiology has been able to measure it beautifully and treat it almost not at all.
That's finally starting to change in the pharmaceutical world, several injectable RNA-based drugs (pelacarsen, olpasiran, and others) are in late-stage trials designed specifically to lower Lp(a), and the field is watching closely to see whether lowering the number translates into fewer heart attacks and strokes. But as of today, none of them are FDA approved. If you look at a current medication list, there is no approved drug, injectable or otherwise, indicated to lower Lp(a).
Which is what makes the estrogen data so interesting.
What the Research Actually Shows
A 2007 editorial in Menopause, the journal of the North American Menopause Society, laid this out clearly. Thomas Clarkson and Richard Karas, two of the most respected voices in cardiovascular hormone research, reviewed the existing evidence comparing oral versus transdermal estrogen therapy and its effects on cardiovascular risk markers (Clarkson & Karas, Menopause, 2007).
Their summary of the data is striking:
In a study of postmenopausal women given either 2 mg of oral micronized estradiol or a 50 mcg transdermal estradiol patch, the oral group saw LDL cholesterol drop by over 15%, Lp(a) drop by more than 18%, and HDL rise by nearly 15%. The transdermal group saw essentially no change in LDL or Lp(a) at all (Zegura et al., cited in Clarkson & Karas, 2007).
A separate comparison of oral conjugated estrogens versus a transdermal estradiol gel found similar results: meaningful LDL and lipid improvement in the oral group, with a much smaller effect from the transdermal route (Baksu et al., cited in Clarkson & Karas, 2007).
The pattern held even in women with metabolic syndrome, oral estradiol produced statistically significant improvements in HDL and LDL, while the transdermal patch produced only a non-significant trend (Chu et al., cited in Clarkson & Karas, 2007).
The consistent finding across multiple independent studies: oral estrogen changes the lipid profile — including Lp(a) — in ways that transdermal estrogen largely does not.
The "Why" Is in the Liver
This isn't random. It comes down to first-pass hepatic metabolism. When estradiol is taken orally, it passes directly through the liver before reaching general circulation, and the liver is where a large share of estrogen's effects on lipid and lipoprotein production actually happen. Transdermal estrogen bypasses the liver almost entirely, which means you don't get the same lipid benefit.
The editorial also points out that estradiol taken orally, but not transdermally, gets esterified to fatty acids in the liver and those estradiol fatty acid esters were independently associated with improved blood flow in a separate study (Vihma et al., cited in Clarkson & Karas, 2007). It's one more thread pointing to the liver as the site where oral estrogen is doing something transdermal estrogen simply isn't built to do.
The Bigger Picture
What excites me isn't that oral estradiol is a miracle drug. It's that we already have a well-tolerated, decades studied hormone that does something the entire pharmaceutical industry is racing for and so far failing to replicate with purpose built drugs costing enormous amounts of research money. When I see a patient's Lp(a) fall from the 90s into the 30s in four months without a statin in sight, I'm watching thirty years of cardiovascular literature play out in real time in one person's chart.
That's the kind of medicine I want to keep practicing, care that's rooted in the data, personalized to the woman in front of me, and willing to look at hormone therapy as the powerful cardiovascular tool it actually is, not just a menopause symptom fix.
If you have a family history of heart disease, an elevated Lp(a), or you're simply trying to figure out what hormone therapy is for you and which route makes sense for your body, let's talk about it.
References Clarkson TB, Karas RH. Do the cardiovascular disease risks and benefits of oral versus transdermal estrogen therapy differ between perimenopausal and postmenopausal women? Menopause. 2007;14(6):963-967.
With warmth,
Alexis C. Ammons, DNP, MSN, FNP-C, APRN Founder & Family Nurse Practitioner, Her NOVA Wellness
